Immuno-Resistance and Sequencing Symposium

Immuno-Resistance and Sequencing Symposium

A Pre-Conference Program; additional registration is required.

Thursday, Nov. 11, 2021*
7:30 a.m. – 6 p.m. EST

*Dates and times subject to change. 

Program Purpose

While immunotherapy treatments, particularly anti-PD-1 therapies, have improved outcomes for some patients, the issue of post-treatment relapse remains a large problem. The proper choice of treatment after relapse on checkpoint inhibition is therefore a critical issue to solve. This symposium will explore the preclinical and clinical data on sequencing of immunotherapies, in order to improve patient outcomes and ensure the field of immunotherapy remains at the forefront of oncology care.

Program Organizers

  • Elizabeth M. Jaffee, MD Sidney Kimmel Cancer Center, Johns Hopkins University
  • Samir N. Khleif, MD   Georgetown University Medical Center
  • Ira Mellman, PhD –  Genentech
  • Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center

Target Audience

The target audience for this symposium includes basic, translational, and clinical researchers from all work settings with an interest in the biological foundation of resistance to immune checkpoint inhibitors and methods to overcome this.

Learning Objectives

At the conclusion of this activity, participants should be able to:

    • Describe the current understanding of resistance to and relapse on checkpoint inhibitor therapies
    • Outline the biological fundamentals of immunotherapy sequencing and the effects on the immune profile and tumor microenvironment
    • Summarize clinical advancements in sequencing of immune therapies for cancer

Program Schedule*
*Program schedule subject to change. 

Session I: Novel Primary vs. Adaptive Resistance Mechanisms
7:30 – 9:15 a.m. EST

7:30 a.m. EST Introduction
7:35 a.m.  Anti-PD1 Resistance - Different Flavors
Samir Khleif, MD - Georgetown University Medical Center

7:55 a.m.  MHC Expression and Antigen Presentation Loss
Christian Hammer, PhD - Genentech

8:15 a.m.  Pre-existing/Primary Resistance (Genetics)
8:35 a.m. Pre-existing/Primary Resistance (T cell Status/Epigenetics/Myeloid) – Integrated Immune Profile
Padmanee Sharma, MD, PhD - The University of Texas MD Anderson Cancer Center

8:55 a.m. Session I Panel Discussion 

9:15 – 9:30 a.m. Break

Session II: Myths vs. Knowledge on Clinical Therapeutic Mechanisms - Lessons Learned
9:30 – 11:10 a.m. EST

9:30 a.m. Single Agents’ Trials, Lessons Learned - Is OX40/GITR Agonist Dead? 
Andrew D. Weinberg, PhD - Earle A. Chiles Research Institute, Providence Portland Medical Center

9:50 a.m. Single Agents’ Trials, Lessons Learned - An-Antagonist LAG3/TIM3
Vijay K. Kuchroo, DVM, PhD - Center for Neurologic Diseases, BWH

10:10 a.m. Anti-PD1 and IDO Inhibitor - Lessons Learned- Is IDO Inhibitor Dead? 
Lance Leopold, MD - Incyte

10:30 a.m. Anti-PD1 and OX40 Agonists - What did we Learn? Is the Combination Dead?
Elizabeth M. Jaffee, MD - Sidney Kimmel Cancer Center, Johns Hopkins University

10:50 a.m. Session II Panel Discussion 

Session III: Understanding the Biology of Therapeutic Pillars - Targeted Pathways and Future Direction

11:10 a.m. – 2:20 p.m. EST

11:10 a.m. Co-inhibitory Pathways - (Nectin Pathway) / VISTA

11:35 a.m. Co-stimulatory Pathways
12:00 p.m. Lunch Break

1:30 p.m. Cell Metabolism

1:55 p.m. T Cell Signaling - Reprogramming Epigenetic
E. John Wherry, PhD - University of Pennsylvania

Session IV: Resistance Reversal Strategies & Sequencing

2:20 – 4:20 p.m. EST

2:20 p.m. How to Choose Rational Combinations - Anti-PD1 with TIGIT: Why did it Work?

2:40 p.m. T cell Activation and Timing 

3 p.m. DCs
Miriam Merad, MD, PhD - Icahn School of Medicine at Mount Sinai

3:20 p.m. Discovering Resistance - Single cell Analyses

3:40 p.m. Autophagy and Phagocytosis

4 p.m. Session IV Panel Discussion – Rational Combination Design

4:20 – 4:35 p.m. Break

Session V: Developmental Process

4:35 – 6 p.m. EST

 4:35 p.m. Appropriate Preclinical Data for Single Agents- What Preclinical Data?

4:55 p.m. Is Single-agent Activity Required for Approval of Combination?  Combinations of Agents without Single-agent Activity - Agonists

5:15 p.m. Regulatory Aspects of Combination or Sequential Therapy

5:35 p.m. Session V Panel Discussion

5:55 p.m. Closing Remarks